Overview

An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

Status:
Completed
Trial end date:
2019-10-31
Target enrollment:
Participant gender:
Summary
This is an extension study to evaluate the long-term safety and tolerability of ABT-SLV187 in subjects with advanced Parkinson's disease.
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie
Treatments:
Antiparkinson Agents
Carbidopa
Levodopa